{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:55:42Z","timestamp":1791658542490,"version":"4.3.4"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Gene therapy is an innovative treatment for Primary Immune Deficiencies (PIDs) that uses autologous hematopoietic stem cell transplantation to deliver stem cells with added or edited versions of the missing or malfunctioning gene that causes the PID. Initial studies of gene therapy for PIDs in the 1990\u20132000's used integrating murine gamma-retroviral vectors. While these studies showed clinical efficacy in many cases, especially with the administration of marrow cytoreductive conditioning before cell re-infusion, these vectors caused genotoxicity and development of leukoproliferative disorders in several patients. More recent studies used lentiviral vectors in which the enhancer elements of the long terminal repeats self-inactivate during reverse transcription (\u201cSIN\u201d vectors). These SIN vectors have excellent safety profiles and have not been reported to cause any clinically significant genotoxicity. Gene therapy has successfully treated several PIDs including Adenosine Deaminase Severe Combined Immunodeficiency (SCID), X-linked SCID, Artemis SCID, Wiskott-Aldrich Syndrome, X-linked Chronic Granulomatous Disease and Leukocyte Adhesion Deficiency-I. In all, gene therapy for PIDs has progressed over the recent decades to be equal or better than allogeneic HSCT in terms of efficacy and safety. Further improvements in methods should lead to more consistent and reliable efficacy from gene therapy for a growing list of PIDs.<\/jats:p>","DOI":"10.3389\/fimmu.2021.648951","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T05:32:05Z","timestamp":1614231125000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":65,"title":["Gene Therapies for Primary Immune Deficiencies"],"prefix":"10.3389","volume":"12","author":[{"given":"Lisa A.","family":"Kohn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald B.","family":"Kohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1126\/science.288.5466.669","article-title":"Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease","volume":"288","author":"Cavazzana-Calvo","year":"2000","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1126\/science.1070104","article-title":"Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning","volume":"296","author":"Aiuti","year":"2002","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-020-00298-5","article-title":"Gene therapy using haematopoietic stem and progenitor cells","author":"Ferrari","year":"2020","journal-title":"Nat Rev Genet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/S0140-6736(72)92345-8","article-title":"Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity","volume":"300","author":"Giblett","year":"1972","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1073\/pnas.75.1.472","article-title":"Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency","volume":"75","author":"Cohen","year":"1978","journal-title":"Proc Natl Acad Sci"},{"key":"B6","article-title":"Adenosine deaminase deficiency","volume-title":"GeneReviews","author":"Hershfield","year":"2017"},{"key":"B7","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s10875-017-0433-3","article-title":"Adenosine deaminase (ADA)-deficient severe combined immune deficiency (SCID): molecular pathogenesis and clinical manifestations","volume":"37","author":"Bradford","year":"2017","journal-title":"J Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1056\/NEJM197612092952402","article-title":"Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency","volume":"295","author":"Polmar","year":"1976","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJM198703053161005","article-title":"Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase","volume":"316","author":"Hershfield","year":"1987","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.clim.2005.07.006","article-title":"Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID)","volume":"117","author":"Chan","year":"2005","journal-title":"Clin Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1056\/NEJM197504032921402","article-title":"Severe combined immunodeficiency and adenosine deaminase deficiency","volume":"1292","author":"Parkman","year":"1975","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1182\/blood-2011-12-396879","article-title":"Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency","volume":"120","author":"Hassan","year":"2012","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s10875-018-0485-z","article-title":"Adenosine deaminase (ADA)-deficient severe combined immune deficiency (SCID): analysis of cases enrolled in protocols of the primary immune deficiency treatment consortium (PIDTC)","volume":"38","author":"Kuo","year":"2018","journal-title":"J Clin Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1126\/science.270.5235.475","article-title":"T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years","volume":"270","author":"Blaese","year":"1995","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1182\/blood-2002-09-2800","article-title":"Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial","volume":"101","author":"Muul","year":"2003","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa0805817","article-title":"Gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"360","author":"Aiuti","year":"2009","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2016-01-688226","article-title":"Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"128","author":"Cicalese","year":"2016","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.ymthe.2017.12.022","article-title":"Gene therapy for adenosine deaminase deficiency: a comprehensive evaluation of short- and medium-term safety","volume":"26","author":"Cicalese","year":"2018","journal-title":"Mol Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ymthe.2006.06.007","article-title":"Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning","volume":"14","author":"Gaspar","year":"2006","journal-title":"Mol Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1182\/blood-2012-02-400937","article-title":"Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans","volume":"120","author":"Candotti","year":"2012","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1172\/JCI90367","article-title":"Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency","volume":"127","author":"Shaw","year":"2017","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","first-page":"97ra80","DOI":"10.1126\/scitranslmed.3002716","article-title":"Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci Transl Med"},{"key":"B23","article-title":"Autologous ex vivo lentiviral gene therapy for adenosine deaminase deficiency","author":"Kohn","year":"","journal-title":"New Engl J Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.jaci.2018.08.024","article-title":"Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency","volume":"143","author":"Kohn","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaci.2018.08.027","article-title":"The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018)","volume":"143","author":"Dvorak","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJMoa012616","article-title":"Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy","volume":"346","author":"Hacein-Bey-Abina","year":"2002","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1056\/NEJMoa1000164","article-title":"Efficacy of gene therapy for X-linked severe combined immunodeficiency","volume":"363","author":"Hacein-Bey-Abina","year":"2010","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(04)17590-9","article-title":"Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector","volume":"364","author":"Gaspar","year":"2004","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"97ra79","DOI":"10.1126\/scitranslmed.3002715","article-title":"Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci Transl Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J Clin Invest"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J Clin Invest"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e20190607","DOI":"10.1084\/jem.20190607","article-title":"Gene therapy for severe combined immunodeficiencies and beyond","volume":"217","author":"Fischer","year":"2020","journal-title":"J Exp. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"97ps36","DOI":"10.1126\/scitranslmed.3002594","article-title":"A tale of two SCIDs","volume":"3","author":"Shaw","year":"2011","journal-title":"Sci Transl Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMoa1404588","article-title":"A modified \u03b3-retrovirus vector for X-linked severe combined immunodeficiency","volume":"371","author":"Hacein-Bey-Abina","year":"2014","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene therapy in patients with transfusion-dependent \u03b2-thalassemia","volume":"378","author":"Thompson","year":"2018","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1182\/blood-2020-142484","article-title":"A phase 1\/2 study of lentiviral-mediated ex-vivo gene therapy for pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I): results from phase 1","volume":"136","author":"Kohn","year":"2020","journal-title":"Blood."},{"key":"B37","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1815408","article-title":"Lentiviral Gene therapy combined with low-dose busulfan in infants with SCID-X1","volume":"380","author":"Mamcarz","year":"2019","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"335ra57","DOI":"10.1126\/scitranslmed.aad8856","article-title":"Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency","volume":"8","author":"De Ravin","year":"2016","journal-title":"Sci Transl Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.omtm.2018.03.002","article-title":"Preclinical development of a lentiviral vector for gene therapy of X-linked severe combined immunodeficiency","volume":"9","author":"Poletti","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B40","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1182\/blood-2013-01-476432","article-title":"SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID","volume":"123","author":"Schuetz","year":"2014","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.bbmt.2019.12.589","article-title":"Early outcome of a phase I\/II clinical trial of gene-corrected autologous CD34+ hematopoietic cells and low-exposure busulfan in patients with artemis-deficient severe combined immunodeficiency","volume":"40","author":"Cowan","year":"2020","journal-title":"J Clin Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/MOH.0b013e32834114bc","article-title":"Clinical spectrum, pathophysiology and treatment of the Wiskott-Aldrich syndrome","volume":"18","author":"Albert","year":"2011","journal-title":"Curr Opin Hematol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/ACI.0b013e32834c230c","article-title":"Gene therapy for the Wiskott-Aldrich syndrome","volume":"11","author":"Galy","year":"2011","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.iac.2010.02.001","article-title":"Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: advances in biology and future directions for treatment","volume":"30","author":"Pai","year":"2010","journal-title":"Immunol Allergy Clin North Am"},{"key":"B45","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/MOH.0b013e3282f30448","article-title":"Wiskott-Aldrich syndrome","volume":"15","author":"Notarangelo","year":"2008","journal-title":"Curr Opin Hematol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood-2010-11-319376","article-title":"Long-term outcome and lineage-specific chimerism in 194 Wiskott-Aldrich syndrome patients treated by hematopoietic cell transplantation between 1980\u20132009: an international collaborative study","volume":"118","author":"Moratto","year":"2011","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1182\/blood.2019002939","article-title":"Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report","volume":"135","author":"Burroughs","year":"2020","journal-title":"Blood."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1056\/NEJMoa1003548","article-title":"Stem-cell gene therapy for the Wiskott-Aldrich syndrome","volume":"363","author":"Boztug","year":"2010","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"227ra33","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott-Aldrich syndrome\u2013long-term efficacy and genotoxicity","volume":"6","author":"Braun","year":"2014","journal-title":"Sci Transl Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41573-019-0020-9","article-title":"Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges","volume":"18","author":"Cavazzana","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B51","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jaci.2020.06.018","article-title":"Gene therapy for Wiskott-Aldrich syndrome: history, new vectors, future directions","volume":"146","author":"Ferrua","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1233151","DOI":"10.1126\/science.1233151","article-title":"Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome","volume":"341","author":"Aiuti","year":"2013","journal-title":"Science"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1016\/S2352-3026(19)30021-3","article-title":"Lentiviral haemopoietic stem\/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1\/2 clinical study","volume":"6","author":"Aiuti","year":"2019","journal-title":"Lancet Haematol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1001\/jama.2015.3253","article-title":"Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome","volume":"313","author":"Hacein-Bey Abina","year":"2015","journal-title":"JAMA"},{"key":"B55","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.jaci.2019.03.012","article-title":"Lentiviral gene therapy corrects platelet phenotype and function in patients with Wiskott-Aldrich syndrome","volume":"144","author":"Sereni","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.1182\/blood-2019-126161","article-title":"Outcome of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome","volume":"134","author":"Labrosse","year":"2019","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1182\/blood-2017-04-777136","article-title":"Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult","volume":"130","author":"Morris","year":"2017","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S0140-6736(66)90238-8","article-title":"Fatal granulomatous disease of childhood. An inborn abnormality of phagocytic function","volume":"1","author":"Holmes","year":"1966","journal-title":"Lancet"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1007\/s12325-017-0636-2","article-title":"A review of chronic granulomatous disease","volume":"34","author":"Arnold","year":"2017","journal-title":"Adv Ther"},{"key":"B60","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S0140-6736(13)62069-3","article-title":"Inborn errors working party of the European Society for Blood and Marrow Transplantation. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study","volume":"383","author":"G\u00fcng\u00f6r","year":"2014","journal-title":"Lancet"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1182\/blood.2020005590","article-title":"Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults","volume":"136","author":"Chiesa","year":"2020","journal-title":"Blood."},{"key":"B62","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s10875-019-00659-8","article-title":"Chronic granulomatous disease-associated IBD resolves and does not adversely impact survival following allogeneic HCT","volume":"39","author":"Marsh","year":"2019","journal-title":"J Clin Immunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"12133","DOI":"10.1073\/pnas.94.22.12133","article-title":"Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease","volume":"94","author":"Malech","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"B64","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1182\/blood-2009-05-222760","article-title":"Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils","volume":"115","author":"Kang","year":"2010","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1038\/mt.2011.166","article-title":"Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I\/II trial","volume":"19","author":"Kang","year":"2011","journal-title":"Mol Ther"},{"key":"B66","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nm1393","article-title":"Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1","volume":"12","author":"Ott","year":"2006","journal-title":"Nat Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/nm.2088","article-title":"Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease","volume":"16","author":"Stein","year":"2010","journal-title":"Nat Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2174\/1566523215666150515145255","article-title":"Successful combination of sequential gene therapy and rescue Allo-HSCT in two children with X-CGD - importance of timing","volume":"15","author":"Siler","year":"2015","journal-title":"Curr Gene Ther"},{"key":"B69","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/mt.2010.226","article-title":"Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells","volume":"19","author":"Santilli","year":"2011","journal-title":"Mol Ther"},{"key":"B70","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41591-019-0735-5","article-title":"Lentiviral gene therapy for X-linked chronic granulomatous disease","volume":"26","author":"Kohn","year":"2020","journal-title":"Nat Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jaci.2017.04.035","article-title":"X-linked carriers of chronic granulomatous disease: illness, lyonization, and stability","volume":"141","author":"Marciano","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jaci.2015.11.028","article-title":"Hyperinflammation in patients with chronic granulomatous disease leads to impairment of hematopoietic stem cell functions","volume":"138","author":"Weisser","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ymthe.2020.09.030","article-title":"Hematopoietic tumors in a mouse model of X-linked chronic granulomatous disease after lentiviral vector-mediated gene therapy","volume":"29","author":"Jofra Hern\u00e1ndez","year":"2021","journal-title":"Mol Ther"},{"key":"B74","first-page":"39","article-title":"Leukocyte adhesion deficiency: molecular basis and functional consequences","volume":"1","author":"Fischer","year":"1998","journal-title":"Immunodefic Rev"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.jaip.2017.12.008","article-title":"Leukocyte adhesion deficiency-I: A comprehensive review of all published cases","volume":"6","author":"Novoa","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1056\/NEJMoa1612197","article-title":"Interleukin-12 and interleukin-23 blockade in leukocyte adhesion deficiency type 1","volume":"376","author":"Moutsopoulos","year":"2017","journal-title":"N Engl J Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1182\/blood.V86.4.1629.bloodjournal8641629","article-title":"Results of allogeneic bone marrow transplantation in patients with leukocyte adhesion deficiency","volume":"86","author":"Thomas","year":"1995","journal-title":"Blood"},{"key":"B78","first-page":"383","article-title":"Gene therapy for leukocyte adhesion deficiency","volume":"2","author":"Bauer","year":"2000","journal-title":"Curr Opin Mol Ther"},{"key":"B79","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1182\/blood-2006-03-006908","article-title":"Correction of the disease phenotype in canine leukocyte adhesion deficiency using ex vivo hematopoietic stem cell gene therapy","volume":"108","author":"Bauer","year":"2006","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","first-page":"113692","DOI":"10.1016\/j.bcp.2019.113692","article-title":"Mouse models in hematopoietic stem cell gene therapy and genome editing","volume":"174","author":"Radtke","year":"2020","journal-title":"Biochem. Pharmacol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jaci.2014.04.033","article-title":"Successful RAG1-SCID gene therapy depends on the level of RAG1 expression","volume":"134","author":"Pike-Overzet","year":"2014","journal-title":"J Allergy Clin Immunol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1084\/jem.20110580","article-title":"Gain-of-function mutations in interleukin-7 receptor-\u03b1 (IL7R) in childhood acute lymphoblastic leukemias","volume":"208","author":"Shochat","year":"2011","journal-title":"J Exp Med"},{"key":"B83","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/1074-7613(95)90026-8","article-title":"Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain","volume":"2","author":"Li","year":"1995","journal-title":"Immunity"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/3233","article-title":"Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice","volume":"4","author":"Brown","year":"1998","journal-title":"Nat Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/sj.cgt.7700232","article-title":"Lymphoid abnormalities in CD40 ligand transgenic mice suggest the need for tight regulation in gene therapy approaches to hyper immunoglobulin M (IgM) syndrome","volume":"7","author":"Sacco","year":"2000","journal-title":"Cancer Gene Ther"},{"key":"B86","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/jgm.1370","article-title":"Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures","volume":"11","author":"Ansorge","year":"2009","journal-title":"J Gene Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"5104","DOI":"10.1182\/blood-2008-11-191049","article-title":"Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection","volume":"113","author":"Throm","year":"2009","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","first-page":"9873","DOI":"10.1128\/JVI.72.12.9873-9880.1998","article-title":"Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery","volume":"72","author":"Zufferey","year":"1998","journal-title":"J Virol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.stem.2018.12.003","article-title":"Lentiviral gene therapy in HSCs restores lineage-specific Foxp3 expression and suppresses autoimmunity in a mouse model of IPEX syndrome","volume":"24","author":"Masiuk","year":"2019","journal-title":"Cell Stem Cell"},{"key":"B90","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1016\/j.celrep.2018.04.103","article-title":"Site-specific gene editing of human hematopoietic stem cells for X-linked hyper-IgM syndrome","volume":"23","author":"Kuo","year":"2018","journal-title":"Cell Rep"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.iac.2018.08.002","article-title":"Newborn screening for severe combined immunodeficiency in the United States: lessons learned","volume":"39","author":"Dorsey","year":"2019","journal-title":"Immunol Allergy Clin North Am"},{"key":"B92","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1182\/blood-2018-06-853879","article-title":"Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice","volume":"133","author":"Kwon","year":"2019","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nbt.3584","article-title":"Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin","volume":"34","author":"Palchaudhuri","year":"2016","journal-title":"Nat Biotechnol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.648951\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T05:32:10Z","timestamp":1614231130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.648951\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":93,"alternative-id":["10.3389\/fimmu.2021.648951"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.648951","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]},"article-number":"648951"}}